Unexpected B Lymphocytes Depletion in a Patient with Pemphigus Vulgaris after a Single Dose of 50 Mg Rituximab.
Rui Wang,Ruoyu Li,Mingyue Wang
DOI: https://doi.org/10.1111/1346-8138.17281
2024-01-01
Abstract:The Journal of DermatologyEarly View LETTER TO THE EDITOR Unexpected B lymphocytes depletion in a patient with pemphigus vulgaris after a single dose of 50 mg rituximab Rui Wang, Rui Wang Department of Dermatology, Peking University First Hospital, Beijing, China National Clinical Research Center for Skin and Immune Diseases, Beijing, China Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, ChinaSearch for more papers by this authorRuoyu Li, Ruoyu Li Department of Dermatology, Peking University First Hospital, Beijing, China National Clinical Research Center for Skin and Immune Diseases, Beijing, China Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, ChinaSearch for more papers by this authorMingyue Wang, Corresponding Author Mingyue Wang [email protected] orcid.org/0000-0001-8317-3414 Department of Dermatology, Peking University First Hospital, Beijing, China National Clinical Research Center for Skin and Immune Diseases, Beijing, China Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China Correspondence Mingyue Wang, Department of Dermatology, Peking University First Hospital, Beijing 100034, China. Email: [email protected]Search for more papers by this author Rui Wang, Rui Wang Department of Dermatology, Peking University First Hospital, Beijing, China National Clinical Research Center for Skin and Immune Diseases, Beijing, China Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, ChinaSearch for more papers by this authorRuoyu Li, Ruoyu Li Department of Dermatology, Peking University First Hospital, Beijing, China National Clinical Research Center for Skin and Immune Diseases, Beijing, China Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, ChinaSearch for more papers by this authorMingyue Wang, Corresponding Author Mingyue Wang [email protected] orcid.org/0000-0001-8317-3414 Department of Dermatology, Peking University First Hospital, Beijing, China National Clinical Research Center for Skin and Immune Diseases, Beijing, China Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China Correspondence Mingyue Wang, Department of Dermatology, Peking University First Hospital, Beijing 100034, China. Email: [email protected]Search for more papers by this author First published: 22 May 2024 https://doi.org/10.1111/1346-8138.17281Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts [J]. J Am Acad Dermatol. 2020; 82: 575–585.e1. 10.1016/j.jaad.2018.02.021 PubMedWeb of Science®Google Scholar 2Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus [J]. Brit J Dermatol. 2012; 166: 405–412. 10.1111/j.1365-2133.2011.10663.x CASPubMedWeb of Science®Google Scholar 3Simpson K, Low ZM, Yap T, Kern JS, Scardamaglia L. Ultralow-dose rituximab in pemphigus: a single-centre experience [J]. Brit J Dermatol. 2022; 186: 581–583. 10.1111/bjd.20819 CASPubMedWeb of Science®Google Scholar 4Russo I, Miotto S, Saponeri A, Alaibac M. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study [J]. Expert Opin Biol Ther. 2020; 20: 673–678. 10.1080/14712598.2020.1727440 CASPubMedWeb of Science®Google Scholar 5Schoergenhofer C, Schwameis M, Firbas C, Bartko J, Derhaschnig U, Mader RM, et al. Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing [J]. Sci Rep-Uk. 2018; 8: 8. PubMedGoogle Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation